| Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript |
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis Deliargyris - Chief Medical Officer Pete Mariani - Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C. Wainwright Michael Kim - Zacks Small-Capital Research Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-15 01:37:47 |
Czytaj oryginał (ang.) |
| CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update |
PRINCETON, N.J. , May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights. |
prnewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Provides Regulatory Update for DrugSorb-ATR |
PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device. |
prnewswire.com |
2025-05-01 20:15:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights |
PRINCETON, N.J. , April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. |
prnewswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program |
PRINCETON, N.J. , April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA). |
prnewswire.com |
2025-04-21 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller |
Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J. , April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller. |
prnewswire.com |
2025-04-17 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America |
PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. |
prnewswire.com |
2025-04-14 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants |
PRINCETON, N.J. , April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the "Series B Right Warrants") issued in the Company's Rights Offering in January 2025. |
prnewswire.com |
2025-04-04 11:00:00 |
Czytaj oryginał (ang.) |
| Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript |
Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Adanna Alexander – IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H. C. Wainwright Thomas Kerr - Zacks Small Cap Research Operator Good afternoon, ladies and gentleman and welcome to the CytoSorbents' Corporation Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlight Conference Call. |
seekingalpha.com |
2025-03-31 23:51:57 |
Czytaj oryginał (ang.) |
| CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet Strengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of Revenue PRINCETON, N.J. |
prnewswire.com |
2025-03-31 20:15:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit |
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release. |
prnewswire.com |
2025-03-21 09:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller |
PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it is postponing its previously announced earnings call scheduled for March 6, 2025 to allow more time to complete the annual financial audit following the recent passing of the Company's Vice President and Corporate Controller from natural causes. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue |
Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J. |
globenewswire.com |
2025-01-03 09:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week |
PRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will host in-person investors meetings in San Francisco alongside the 43rd Annual J.P. |
globenewswire.com |
2024-12-12 09:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India |
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. |
globenewswire.com |
2024-11-11 09:30:00 |
Czytaj oryginał (ang.) |
| Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript |
Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today. |
seekingalpha.com |
2024-11-09 15:20:58 |
Czytaj oryginał (ang.) |
| CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update |
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor |
globenewswire.com |
2024-10-01 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference |
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. |
globenewswire.com |
2024-08-27 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it granted inducement equity awards on August 14, 2024 (the “Grant Date”) to its newly-hired Chief Financial Officer, Peter J. Mariani. |
globenewswire.com |
2024-08-16 20:05:00 |
Czytaj oryginał (ang.) |
| Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript |
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Eric Ribner - IR Phillip Chan - CEO Kathleen Bloch - CFO Vincent Capponi - President & COO Makis Deliargyris - Chief Medical Officer Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Yuan Zhi - B. Riley Securities Tom Kerr - Zacks Investment Research Sean Lee - H.C. |
seekingalpha.com |
2024-08-14 02:31:02 |
Czytaj oryginał (ang.) |
| CytoSorbents Reports Second Quarter 2024 Financial and Operational Results |
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-13 20:19:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Appoints Peter J. Mariani Chief Financial Officer |
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. |
globenewswire.com |
2024-08-13 20:18:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Report Second Quarter 2024 Operating and Financial Results |
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024. |
globenewswire.com |
2024-08-07 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement |
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share. |
globenewswire.com |
2024-08-01 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website |
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com. |
globenewswire.com |
2024-07-30 06:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress |
CytoSorbents CEO Dr. Phillip Chan to highlight its innovative critical care and cardiac surgery blood purification therapy at AAPI Conference this weekend |
globenewswire.com |
2024-07-17 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents Secures $20 Million Credit Facility |
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P. |
globenewswire.com |
2024-07-02 11:00:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting |
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its 2024 Virtual Annual Stockholders Meeting tomorrow, June 6, 2024 at 10 AM EDT. |
globenewswire.com |
2024-06-05 11:00:00 |
Czytaj oryginał (ang.) |
| B. Riley Weighs in on Cytosorbents Co.’s Q2 2024 Earnings (NASDAQ:CTSO) |
Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Equities research analysts at B. Riley dropped their Q2 2024 earnings per share estimates for Cytosorbents in a research note issued on Wednesday, May 15th. B. Riley analyst Y. Zhi now forecasts that the medical research company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.07). B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.35) per share. B. Riley also issued estimates for Cytosorbents’ Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.34) EPS and FY2025 earnings at ($0.28) EPS. Cytosorbents (NASDAQ:CTSO – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The firm had revenue of $9.79 million for the quarter, compared to the consensus estimate of $9.78 million. During the same quarter last year, the business posted ($0.17) earnings per share. CTSO has been the subject of a number of other reports. StockNews.com initiated coverage on Cytosorbents in a report on Saturday. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Tuesday, May 7th. Get Our Latest Research Report on CTSO Cytosorbents Stock Performance Shares of Cytosorbents stock opened at $0.97 on Monday. Cytosorbents has a one year low of $0.78 and a one year high of $4.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.21 and a current ratio of 1.49. The company has a market cap of $52.55 million, a price-to-earnings ratio of -1.64 and a beta of 0.62. The business’s 50 day moving average price is $0.89 and its 200 day moving average price is $1.07. Institutional Trading of Cytosorbents Several hedge funds have recently made changes to their positions in the business. Key Client Fiduciary Advisors LLC boosted its stake in shares of Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares during the period. Raymond James & Associates purchased a new position in Cytosorbents in the fourth quarter worth approximately $56,000. Sargent Investment Group LLC lifted its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Avenir Corp lifted its stake in Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock. About Cytosorbents (Get Free Report) Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. |
https://www.defenseworld.net |
2024-05-20 05:38:41 |
Czytaj oryginał (ang.) |
| Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript |
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Eric Ribner - Investor Relations Phil Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Chief Financial Officer Makis Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President, Sales and Marketing Christopher Cramer - Senior Vice President, Business Development Conference Call Participants Yuan Zhi - B. Riley Securities Sean Lee - H.C. |
seekingalpha.com |
2024-05-10 03:01:03 |
Czytaj oryginał (ang.) |
| CytoSorbents Reports First Quarter 2024 Results |
Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024. |
globenewswire.com |
2024-05-09 20:17:00 |
Czytaj oryginał (ang.) |
| CytoSorbents to Report First Quarter 2024 Operating and Financial Results |
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024. |
globenewswire.com |
2024-04-26 11:00:00 |
Czytaj oryginał (ang.) |